We detected that mice treated with high doses of TSLP showed a significant decrease (p = 0.0006, 0.0025, 0.001, and <0.0001 for weeks 2, 3, 4, and 5, respectively) in leukemia burden, when compared to those treated with low doses of TSLP (Figure 2B). This evidence concerns the gene TSLP and leukemia.